Trials / Completed
CompletedNCT01559038
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 483 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
Conditions
Timeline
- Start date
- 2012-02-16
- Primary completion
- 2019-11-19
- Completion
- 2019-11-19
- First posted
- 2012-03-21
- Last updated
- 2020-11-19
Locations
41 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01559038. Inclusion in this directory is not an endorsement.